Rhythm Pharmaceuticals, Inc.
RYTM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $130 | $77 | $24 | $3 |
| % Growth | 68.1% | 227.6% | 649.5% | – |
| Cost of Goods Sold | $13 | $9 | $2 | $1 |
| Gross Profit | $117 | $68 | $22 | $3 |
| % Margin | 89.7% | 88% | 91% | 81% |
| R&D Expenses | $238 | $135 | $109 | $104 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $144 | $118 | $92 | $68 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $382 | $252 | $201 | $173 |
| Operating Income | -$266 | -$184 | -$179 | -$170 |
| % Margin | -204% | -238.1% | -757.9% | -5,391.9% |
| Other Income/Exp. Net | $5 | $0 | -$2 | $100 |
| Pre-Tax Income | -$260 | -$184 | -$181 | -$70 |
| Tax Expense | $0 | $1 | $0 | $0 |
| Net Income | -$261 | -$185 | -$181 | -$70 |
| % Margin | -200.3% | -238.5% | -766.2% | -2,207.1% |
| EPS | -4.34 | -3.2 | -3.51 | -1.37 |
| % Growth | -35.6% | 8.8% | -156.2% | – |
| EPS Diluted | -4.34 | -3.2 | -3.51 | -1.37 |
| Weighted Avg Shares Out | 61 | 58 | 52 | 50 |
| Weighted Avg Shares Out Dil | 61 | 58 | 52 | 50 |
| Supplemental Information | – | – | – | – |
| Interest Income | $15 | $14 | $4 | $0 |
| Interest Expense | $21 | $14 | $5 | $0 |
| Depreciation & Amortization | $2 | $2 | $2 | $1 |
| EBITDA | -$238 | -$168 | -$174 | -$68 |
| % Margin | -183% | -217.6% | -737.1% | -2,170.4% |